Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
28 April 2021 - 10:05PM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the
“Company”), a specialty biopharmaceutical company commercializing
and developing therapeutics and diagnostic tests, today announced
its Annual General Meeting ("AGM") will be held on May 5, 2021 at
10:00 a.m. ET. Due to the impact of the COVID-19 pandemic, the
meeting will be held virtually.
Shareholders will not be able to attend the AGM
in-person at a physical location. However, the platform for the
virtual AGM will provide shareholders as of the close of business
on March 30, 2021, the ability to listen to the AGM live, submit
questions and submit their vote during the meeting.
To be admitted to the virtual AGM, shareholders
need to visit www.virtualshareholdermeeting.com/AEZS2021 and enter
the control number included on the proxy form or voting instruction
form, as applicable. Online check-in will begin 15 minutes prior,
at 9:45 a.m. ET. The AGM will begin promptly at 10:00 a.m. ET on
May 5, 2021. If you are planning to attend the AGM, please refer to
and observe the "Rules of Conduct and Procedures" available
here.
Aeterna Zentaris strongly encourages its
shareholders to read its management proxy circular dated April 5,
2021 and other AGM materials carefully. If you are unable to attend
the AGM or if you wish to vote in advance of the AGM, please
carefully follow the instructions on the proxy or voting
instruction form. Shareholders that hold their common shares with a
bank, broker or financial intermediary that wish to vote at the AGM
must carefully follow the instructions provided by their
intermediary. In order to be effective, proxies must be received by
the Chair of the AGM no later than 48 hours (if voting by mail) or
24 hours (if voting by telephone or Internet) prior to the close of
business on the date of the AGM or any adjournment or postponement
thereof. The time limit for the deposit of proxies may be waived by
the Chair of the AGM without notice. If you are attending the AGM,
please log-on to the virtual meeting in advance to ensure that your
vote will be counted.
Even if shareholders intend to attend the
virtual AGM, it is strongly recommended that votes are made in
advance by telephone or Internet to ensure that votes are received
before the AGM. To cast your vote by telephone or Internet, please
have your proxy card or voting instruction form in hand and
carefully follow the instructions contained therein. Your telephone
or Internet vote authorizes the named proxies to vote your common
shares in the same manner as if you mark, sign and return your
proxy card. If shareholders of record vote by mail, your vote must
be received before 5:00 p.m. ET on Monday, May 3, 2021. If
shareholders of record vote by telephone or Internet, your vote
must be received before 5:00 p.m. ET on May 4, 2021.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
macimorelin, is the first and only U.S. FDA and European Commission
approved oral test indicated for the diagnosis of adult growth
hormone deficiency (AGHD). Macimorelin is currently marketed in the
United States under the tradename Macrilen™ through a license
agreement with Novo Nordisk where Aeterna receives royalties on net
sales. According to a commercialization and supply agreement,
MegaPharm Ltd. will seek regulatory approval and then commercialize
macimorelin in Israel and the Palestinian Authority. Additionally,
upon receipt of pricing and reimbursement approvals, Aeterna
expects that macimorelin will be marketed in Europe and the United
Kingdom through a recently established license agreement with
Consilient Health Ltd. and Aeterna will receive royalties on net
sales and other potential payments.Aeterna is also leveraging the
clinical success and compelling safety profile of macimorelin to
develop it for the diagnosis of childhood-onset growth hormone
deficiency (CGHD), an area of significant unmet need.
Aeterna is actively pursuing business
development opportunities for the commercialization of macimorelin
in Asia and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit www.zentaris.com and connect with the Company
on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking
statements (as defined by applicable securities legislation) made
pursuant to the safe-harbor provision of the U.S. Securities
Litigation Reform Act of 1995, which reflect our current
expectations regarding future events. Forward-looking statements in
this press release include statements regarding the holding of,
attending, and voting before and at, the AGM and those relating to
Aeterna’s expectation that, upon receipt of pricing and
reimbursement approvals, macimorelin will be marketed in Europe and
the United Kingdom. Forward-looking statements involve known and
unknown risks and uncertainties, and other factors which may cause
the actual results, performance or achievements stated herein to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
information. Actual results could differ materially from those
currently anticipated due to a number of factors and risks,
including, without limitation, Aeterna‘s ability to obtain receipt
of pricing and reimbursement approvals as well as those risks
discussed in our Annual Report on Form 20-F, under the caption "Key
Information Risk Factors" filed with the relevant Canadian
securities regulatory authorities in lieu of an annual information
form and with the U.S. Securities and Exchange Commission. Given
the uncertainties and risk factors, readers are cautioned not to
place undue reliance on these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments,
unless required to do so by a governmental authority or applicable
law.
No securities regulatory authority has either
approved or disapproved of the contents of this news release. The
Toronto Stock Exchange accepts no responsibility for the adequacy
or accuracy of this release.
Investor Contact:
Jenene ThomasJTC TeamT (US): +1 (833) 475-8247E:
aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2024 to May 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From May 2023 to May 2024